The CTL4 agonist system described in this study is particularly interesting as a malaria transmission-blocking target because it achieves a level of refractoriness to the human malaria parasite that we have not observed with other genetically modified Anopheles lines, without compromising the life span of adult mosquitoes (S3 Fig). The gene discussed is SLC44A4; the disease is malaria.